Orphanet Journal of Rare Diseases (Jun 2021)

Differences in health care experiences between rare cancer and common cancer patients: results from a national cross-sectional survey

  • Eline de Heus,
  • Vivian Engelen,
  • Irene Dingemans,
  • Carol Richel,
  • Marga Schrieks,
  • Jan Maarten van der Zwan,
  • Marc G. Besselink,
  • Mark I. van Berge Henegouwen,
  • Carla M. L. van Herpen,
  • Saskia F. A. Duijts

DOI
https://doi.org/10.1186/s13023-021-01886-2
Journal volume & issue
Vol. 16, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Background Patients with rare cancers face challenges in the diagnostic and treatment phase, and in access to clinical expertise. Since studies on health care experiences of these patients in comparison to patients with more common cancers are scarce, we aimed to explore these differences. Methods Data were cross-sectionally collected among (former) adult cancer patients through a national online survey in the Netherlands (October 2019). Descriptive statistics were reported and subgroups (rare vs. common patients) were compared. Results In total, 7343 patients (i.e., 1856 rare and 5487 common cancer patients) participated. Rare cancer patients were more often diagnosed and treated in different hospitals compared to common cancer patients (67% vs. 59%, p < 0.001). Rare cancer patients received treatment more often in a single hospital (60% vs. 57%, p = 0.014), but reported more negative experiences when treated in multiple hospitals than common cancer patients (14% vs. 9%, p < 0.001). They also more often received advise from their physician about the hospital to go to for a second opinion (50% vs. 36%, p < 0.001), were more likely to choose a hospital specialized in their cancer type (33% vs. 22%, p < 0.001), and were more willing to travel as long as necessary to receive specialized care than common cancer patients (55% vs. 47%, p < 0.001). Conclusions Rare and common cancer patients differ in their health care experiences. Health care for rare cancer patients can be further improved by proper referral to centers of expertise and building a clinical network specifically for rare cancers.

Keywords